Myriad Genetics Earnings Call Nuggets: Companion Diagnostic and BRACAnalysis

Myriad Genetics, Inc. (NASDAQ:MYGN) recently reported its fourth quarter earnings and discussed the following topics in its earnings conference call.

Companion Diagnostic

Amanda Murphy – William Blair & Company: I just had a question about some of the work you are doing with the pharma companies on the Companion Diagnostic. So, there has been quite a lot of talk about competition, but I am curious how, number one, maybe you could just talk to the process with the FDA, just in terms of timing and data required to get the IDE designation? Then secondly, in terms of your relationship with some of the pharma companies, is it an exclusive arrangement in terms of your ability to be a Companion Diagnostic test for them once they are on the market?

Peter D. Meldrum – President and CEO: Yes. As you pointed out, we have six major collaborations with pharmaceutical companies developing PARP inhibitors. We have submitted and it has been accepted by the FDA, our IDE that as a Companion Diagnostic product will be approved on the same clinical data and in a parallel process with the approval of the drug itself. We are excited about this opportunity. Obviously, we don’t have an exclusive from Myriad’s perspective with the pharma companies. We are free to work with any of the pharma companies that are developing PARP inhibitors. As we work through the regulatory process, we’re working very closely with pharmaceutical companies as collaborators on how best to ensure timely and rapid uptake of their particular drugs.


William Quirk – Piper Jaffray: Just a couple of quick ones for me. One, can you just remind us the BART penetration from BRACAnalysis in the quarter? Then, Jim, maybe you can just elaborate about how you’re thinking about that, is it, as we think about the 2014 guidance?

Mark C. Capone – President, Myriad Genetic Laboratories, Inc.: On BART penetration, rates were, as we mentioned last call, we ended the quarter at around 80%. We’ve seen pretty consistent, 80% penetration throughout the rest of the quarter, through the fourth quarter, as we mentioned, we had done, almost all of the large insurance companies, and there were really only some of the smaller payors that were left and we expected that, that would take some additional time, and so, we didn’t see a major change in the ration of BARTs to BRACAnalysis testing Q4. I think we’ve assumed that, as we go into next year, that we will continue to see essentially that same level of BART reimbursement that we did in the fourth quarter.